[Featured Stock] Samsung Biologics Rises Ahead of JPM Healthcare Conference

Samsung Biologics is showing strength ahead of its participation in the world's largest bio investment event, the JPM Healthcare Conference.

As of 10 a.m. on the 7th, Samsung Biologics is trading at 1,002,000 KRW, up 5.92% from the previous session.

The anticipation for the JPM Healthcare Conference, which will open from the 13th to the 16th (local time) in San Francisco, USA, is believed to be driving this.

At this event, CEO John Rim will introduce this year's business plans, mid-to-long-term vision, and the background of the company's growth.

During the event, Samsung Biologics will focus on strengthening networking to expand its business by promoting its Contract Development and Manufacturing Organization (CDMO) competitiveness through investor meetings.

The JPM Healthcare Conference, held every January, is the largest investment event in the pharmaceutical and bio industry. This year marks its 43rd edition, with around 550 related companies and approximately 8,000 participants expected to attend.